NASDAQ:NKNantkwest Stock Price, Forecast & News

Nantkwest's stock was trading at $3.52 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NK stock has increased by 91.5% and is now trading at $6.74. View which stocks have been most impacted by Coronavirus.

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nantkwest in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A." View analyst ratings for Nantkwest.

Nantkwest is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Nantkwest.

Nantkwest Inc (NASDAQ:NK) posted its quarterly earnings results on Monday, May, 11th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by $0.02. The biotechnology company had revenue of $0.02 million for the quarter. Nantkwest had a negative return on equity of 51.94% and a negative net margin of 112,350.85%. View Nantkwest's earnings history.

0 Wall Street analysts have issued twelve-month price objectives for Nantkwest's stock. Their forecasts range from $10,000,000.00 to $0.00. On average, they expect Nantkwest's stock price to reach $0.00 in the next twelve months. This suggests that the stock has a possible downside of 100.0%. View analysts' price targets for Nantkwest.

News stories about NK stock have been trending extremely negative recently, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Nantkwest earned a media sentiment score of -4.0 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutNantkwest.

Nantkwest saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 4,910,000 shares, an increase of 35.3% from the April 30th total of 3,630,000 shares. Based on an average trading volume of 922,300 shares, the days-to-cover ratio is currently 5.3 days. Approximately 17.7% of the company's stock are short sold. View Nantkwest's Current Options Chain.

Some companies that are related to Nantkwest include Alector (ALEC), Fate Therapeutics (FATE), Bill.com (RVMD), Adverum Biotechnologies (ADVM), SpringWorks Therapeutics (SWTX), Sangamo Therapeutics (SGMO), Twist Bioscience (TWST), Mesoblast (MESO), Editas Medicine (EDIT), Adaptimmune Therapeutics (ADAP), Regenxbio (RGNX), I-Mab (BDTX), Cortexyme (CRTX), Coherus Biosciences (CHRS) and Beam Therapeutics (BEAM). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nantkwest investors own include Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Novavax (NVAX), Mallinckrodt (MNK), Opko Health (OPK), Amicus Therapeutics (FOLD), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Bausch Health Companies (BHC) and Fate Therapeutics (FATE).

(NK) raised $150 million in an IPO on Tuesday, July 28th 2015. The company issued 7,000,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray served as the underwriters for the IPO and MLV & Co. was co-manager.

Nantkwest trades on the NASDAQ under the ticker symbol "NK."

Nantkwest's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (0.69%), Geode Capital Management LLC (0.33%), Morgan Stanley (0.07%), Horizon Kinetics Asset Management LLC (0.05%), Creative Planning (0.05%) and Two Sigma Investments LP (0.04%). Company insiders that own Nantkwest stock include Barry J Simon, John C Thomas and Steve Gorlin. View institutional ownership trends for Nantkwest.

NK stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Horizon Kinetics Asset Management LLC, First Allied Advisory Services Inc., BlackRock Inc., and State Street Corp. Company insiders that have sold Nantkwest company stock in the last year include Barry J Simon, and John C Thomas. View insider buying and selling activity for Nantkwest.

NK stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Two Sigma Investments LP, Deutsche Bank AG, Geode Capital Management LLC, Creative Planning, Invesco Ltd., Squarepoint Ops LLC, and GSA Capital Partners LLP. View insider buying and selling activity for Nantkwest.

Shares of NK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NK stock can currently be purchased for approximately $6.74.

Nantkwest has a market capitalization of $663.96 million and generates $40,000.00 in revenue each year. The biotechnology company earns $-65,790,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Nantkwest employs 161 workers across the globe.

The official website for Nantkwest is www.nantkwest.com.

Nantkwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-633-0300 or via email at [email protected]